Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression

Cancer Research

Volumn 63, Issue 14, 2003, Pages 3877-3882

  Vanaja, Donkena Krishna ^a   Cheville, John C ^a   Iturria, Steve J ^a   Young, Charles Y F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 185;

ADULT; AGED; ARTICLE; BPAG1 GENE; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PSP94 GENE; ZNF185 GENE;

AGED; AUTOANTIGENS; CARRIER PROTEINS; COLLAGEN; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; TRANSCRIPTION, GENETIC;

EID: 0043244946     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., and Epstein, J. I. Pathological and molecular aspects of prostate cancer. Lancet, 361: 955-964, 2003.
2. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
3. Luo, J., Duggan, D. J., Chen, Y., Sauvageot, J., Ewing, C. M., Bittner, M. L., Trent, J. M., and Isaacs, W. B. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res., 61: 4683-4688, 2001.
4. Magee, J. A., Araki, T., Patil, S., Ehrig, T., True, L., Humphrey, P. A., Catalona, W. J., Watson, M. A., and Milbrandt, J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res., 61: 5692-5696, 2001.
5. Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang-Rodriguez, J., Moskaluk, C. A., Frierson, H. F., Jr., and Hampton, G. M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 61: 5974-5978, 2001.
6. Rubin, M. A., Zhou, M., Dhanasekaran, S. M., Varambally, S., Barrette, T. R., Sanda, M. G., Pienta, K. J., Ghiesh, D., and Chinnaiyan, A. M. α-methyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA, 287: 1662-1670, 2002.
7. Ernst, T., Hergenhahn, M., Kenzelmann, M., Cohen, C. D., Bonrouhi, M., Weninger, A., Klaren, R., Grone, E., Wiesel, M., Gudemann, C., Kuster, J., Schott, W., Staehler, G., Kretzler, M., Hollstein, M., and Grone, H. J. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am. J. Pathol., 160: 2169-2180, 2002.
8. Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene, 21: 5400-5413, 2002.
9. Wong, I. H. N., Lo, Y. M. D., and Zhang, J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 59: 71-73, 1999.
10. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
11. Plass, C. Cancer epigenomics. Hum. Mol. Genet., 11: 2479-2488, 2002.
12. Wong, I. H. N., and Lo, Y. M. D. New markers for cancer detection. Cancer Prev., 4: 471-477, 2002.
13. Giordano, T. J., Shedden, K. A., Schwartz, D. R., Kuick, R., Taylor, J. M., Lee, N., Misek, D. E., Greenson, J. K., Kardia, S. L., Beer, D. G., Rennert, G., Cho, K. R., Gruber, S. B., Fearon, E. R., and Hanash, S. Organ-specific molecular classification of primary lung, and ovarian adenocarcinomas using gene expression profiles. Am. J. Pathol., 159: 1231-1238, 2001.
14. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
15. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.
16. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.
17. LaTulippe, E., Satagopan, J., Smith, A., Scher, H., Scardino, P., Reuter, V., and Gerald, W. L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res., 62: 4499-506, 2002.
18. Luo, J. H., Yu, Y. P., Cieply, K., Lin, F., Deflavia, P., Dhir, R., Finkelstein, S., Michalopoulos, G., and Becich, M. Gene expression analysis of prostate cancers. Mol. Carcinog., 33: 25-35, 2002.
19. Shields, J. M., Rogers-Graham, K., and Der, C. J. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J. Biol. Chem., 277: 9790-9799, 2002.
20. Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D., and Chinnaiyan, A. M. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res., 62: 4427-4433, 2002.
21. Stamey, T. A., Warrington, J. A., Caldwell, M. C., Chen, Z., Fan, Z., Mahadevappa, M., McNeal, J. E., Nolley, R., and Zhang, Z. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J. Urol., 166: 2171-2177, 2001.
22. Sakai, H., Tsurusaki, T., Kanda, S., Koji, T., Xuan, J. W., and Saito, Y. Prognostic significance of β-microseminoprotein mRNA expression in prostate cancer. Prostate, 38: 278-284, 1999.
23. Garde, S. V., Basrur, V. S., Finkelman, M. A., Krishnan, A., Wellham, L., Ben-Josef, E., Garde, H. S. V., Basrur, V. S., Finkelman, M. A., Krishnan, A., Wellham, L., Ben-Josef, E., Haddad, M., Taylor, J. D., Porter, A. T., and Tang, D. G. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate, 38: 118-125, 1999.
24. Bergstraesser, L. M., Srinivasan, G., Jones, J. C., Stahl, S., and Weitzman, S. A. Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells. Am. J. Pathol., 147: 1823-1839, 1995.
25. Herold-Mende, C., Kartenbeck, J., Tomakidi, P., and Bosch, F. X. Metastatic growth of squamous cell carcinomas is correlated with upregulation and redistribution of hemidesmosomal components. Cell Tissue Res., 306: 399-408, 2001.
26. Simpson, S., Woodworth, C. D., and DiPaolo, J. A. Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Oncogene, 14: 2149-2157, 1997.
27. Antonyak, M. A., McNeill, C. J., Wakshlag, J. J., Boehm, J. E., Cerione, R. A. Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells. J. Biol. Chem., 278: 15859-15866, 2003.
28. Lozano, E., Betson, M., and Braga, V. M. Tumor progression: small GTPases and loss of cell-cell adhesion. Bioessays, 25: 452-463, 2003.
29. Heiss, N. S., Gloeckner, G., Bachner, D., Kioschis, P., Klauck, S. M., Hinzmann, B., Rosenthal, A., Herman, G. E., and Poustka, A. Genomic structure of a novel LIM domain gene (ZNF185) in Xq28 and comparisons with the orthologous murine transcripts. Genomics, 43: 329-338, 1997.
30. Bach, I. The LIM domain: regulation by association. Mech. Dev., 91: 5-17, 2000.
31. McLoughlin, P., Ehler, E., Carlile, G., Licht, J. D., and Schafer, B. W. The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J. Biol. Chem., 277: 37045-37053, 2002.
32. Mousses, S., Bubendorf, L., Wagner, U., Hostetter, G., Kononen, J., Cornelison, R., Goldberger, N., Elkahloun, A. G., Willi, N., Koivisto, P., Ferhle, W., Raffeld, M., Sauter, G., and Kallioniemi, O. P. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res., 62: 1256-1260, 2002.
33. Yamada, Y., Pannell, R., Forster, A., and Rabbitts, T. H. The LIM-domain protein Lmo2 is a key regulator of tumor angiogenesis: a new anti-angiogenesis drug target. Oncogene, 21: 1309-1315, 2002.
34. Robert, M. F., Morin, S., Beaulieu, N., Gauthier, F., Chute, I. C., Barsalou, A., and MacLeod, A. R. DNMTI is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet., 33: 61-65, 2003.